Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)
Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP
Publisher
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP
Source route
Continue on gsk.com
Leave the platform to read the original full article on the publisher site.
Source: GSK News
Scope: Industry
Related coverage
More related coverage
ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infections
・Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 8...
How we invent
At Merck, we follow the science. Learn about Merck's research and development proccess and see our R...
Translational medicine
Translational medicine across the drug development process
Research & Development
At Zoetis, we're driven by science and purpose. See how we use the most innovative research and tech...